Details

Autor(en) / Beteiligte

• Adiko, Aimé Cézaire
• Bens, Marcelle
• Tandon, Naman
• Benadda, Samira
• Boedec, Erwan
• Pellé, Olivier
• El-Benna, Jamel
• Monteiro, Renato
• Laffargue, Muriel
• Stephens, Len
• Guermonprez, Pierre
• Saveanu, Loredana

Titel

Tickling APCsThe p84/p110 complex of PI3K regulates NOX2 assembly and cross-presentation of immune complexes

Ist Teil von

• Molecular immunology, 2022-10, Vol.150, p.17

Ort / Verlag

Elsevier Ltd

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Antibody-mediated cross-presentation is known to elicit strong CD8+ T cell responses, particularly relevant in cancer therapy. Anti-tumor antibodies are known to rapidly kill cancer cells by antibody-dependent cellular cytotoxicity (ADCC), but the long-term immune control of tumors is based on induction of CD8+ T cell response, which relays on anti-tumor antibody-mediated cross-presentation. The molecular mechanisms by which this pathway of cross-presentation allows to poor cross-presenting cells, such as type 2 dendritic cells (DCs) and monocyte-derived DCs (moDCs), to efficiently cross present are not well understood. We demonstrated that enzymatic activity of p84/p110g complex of PI3Kg regulates the assembly of NADPH oxidase NOX2 and ROS production in type 2 DCs from mouse spleen and murine bone marrow derived DCs, enhancing thus the cross-presentation of immune complexes by these cells. Our results suggest that the association between anti-tumor monoclonal antibodies and PI3Kg inhibitors might block the antibody-mediated cross-presentation of tumor antigens and should be avoided in clinical therapy of cancers.